阿爾茨海默病（Alzheimer’s disease，AD）是一種以學(xué)習(xí)和記憶能力漸進(jìn)性退化為特征的中樞神經(jīng)退行性疾病。隨著人口老齡化的加劇，AD發(fā)病率有逐年增加的趨勢(shì)，對(duì)人們的健康造成嚴(yán)重威脅。目前對(duì)AD的發(fā)病機(jī)制尚未完全闡明，且臨床上仍缺乏治療AD的有效藥物。傳統(tǒng)中藥以其天然成分多活性的特點(diǎn)，在復(fù)雜多因素疾病的治療中占優(yōu)勢(shì)。研究發(fā)現(xiàn)枸杞子的主要活性成分枸杞多糖（Lycium barbarum polysaccharide，LBP）在AD治療方面有一定潛力，表現(xiàn)出抗炎、抗凋亡、保護(hù)線粒體和抗氧化性質(zhì)，能夠發(fā)揮抑制β淀粉樣蛋白異常沉積，抑制Tau蛋白過(guò)度磷酸化，調(diào)節(jié)神經(jīng)遞質(zhì)，恢復(fù)突觸可塑性，調(diào)節(jié)微生物-腸-腦軸，改善胰島素抵抗等功能，從而實(shí)現(xiàn)對(duì)AD的預(yù)防和治療。通過(guò)對(duì)LBP治療AD的藥理分子機(jī)制進(jìn)行分析，為L(zhǎng)BP防治AD的進(jìn)一步研究提供參考。

Alzheimer’s disease (AD) is a neurodegenerative disorder of the central nervous system characterized by progressive deterioration of learning and memory functions. With the intensification of population aging, the incidence of AD continues to rise annually, posing a significant public health threat. Currently, the pathogenesis of AD remains incompletely elucidated, and clinically effective treatments are still lacking. Traditional Chinese medicine (TCM), with its characteristic multi-component composition and multi-target activity, offers advantages in treating complex multifactorial diseases. Studies indicate that Lycium barbarum polysaccharide (LBP), the primary active component of Gouqizi (Lycii Fructus), exhibits promising therapeutic potential for AD through its effects including anti-inflammatory, anti-apoptotic, mitochondrial protective, and anti-oxidant properties and functions of inhibiting β-amyloid (Aβ) abnormal deposition and Tau protein hyperphosphorylation, regulating neurotransmitter, restoring synaptic plasticity, modulating the microbiota-gut-brain axis, and improving insulin resistance, contributing to AD prevention and treatment. This study analyzes the pharmacological mechanisms underlying LBP’s therapeutic effects in AD, providing a reference for future research on the prevention and treatment of AD by LBP.

R285

四川省基層衛(wèi)生中心項(xiàng)目（SWFZ24-Y-70）；南充市社會(huì)科學(xué)界聯(lián)合會(huì)項(xiàng)目（NC25B240）；川北醫(yī)學(xué)院博士啟動(dòng)基金（CBY23-QDA29）